Antiretroviral pharmacology: Special issues regarding pregnant women and neonates

Clinics in Perinatology

Volumn 37, Issue 4, 2010, Pages 907-927

  Mirochnick, Mark ^a   Best, Brookie M ^b   Clarke, Diana F ^c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c BOSTON MEDICAL CENTER   (United States)

Author keywords

Antiretrovirals; Neonates; Pharmacology; Pregnant women

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; HERBACEOUS AGENT; IRON; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; METOCLOPRAMIDE; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROCHLORPERAZINE; PROMETHAZINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANEMIA; AREA UNDER THE CURVE; BONE DENSITY; BONE MARROW SUPPRESSION; BREAST MILK; CARDIOMYOPATHY; CHOLESTATIC HEPATITIS; CLINICAL TRIAL; CONSTIPATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISPOSITION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATTY LIVER; FETUS OUTCOME; GESTATIONAL CARBOHYDRATE INTOLERANCE; GINGER; HEART BLOCK; HEMATOLOGIC DISEASE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPEREMESIS; IC 50; LACTIC ACIDOSIS; LIVER FAILURE; LIVER NECROSIS; LIVER TOXICITY; LOADING DRUG DOSE; LOW DRUG DOSE; MATERNAL CARE; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; NEWBORN ANEMIA; NEWBORN PERIOD; NONHUMAN; PATIENT COMPLIANCE; PERINATAL DRUG EXPOSURE; PREGNANCY; PREGNANCY DIABETES MELLITUS; PREGNANCY OUTCOME; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN ALLERGY; STEVENS JOHNSON SYNDROME; TERATOGENICITY; TREATMENT DURATION; VIRUS ENTRY; VIRUS TRANSMISSION; VOMITING;

ANTI-RETROVIRAL AGENTS; DELIVERY, OBSTETRIC; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MILK, HUMAN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TERATOGENS; TISSUE DISTRIBUTION;

EID: 78449255208     PISSN: 00955108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clp.2010.08.006     Document Type: Review

References (131)

1. Morgan D.J. Drug disposition in mother and foetus. Clin Exp Pharmacol Physiol 1997, 24(11):869-873.
2. Loebstein R., Lalkin A., Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet 1997, 33(5):328-343.
3. Wright L.L., Catz C.S. Drug distribution during fetal life. Fetal and neonatal physiology 1998, 169. WB Saunders, Philadelphia. R.A. Polin, W.W. Fox (Eds.).
4. Krauer B., Krauer F., Hytten F.E. Drug disposition and pharmacokinetics in the maternal-placental-fetal unit. Pharmacol Ther 1980, 10(2):301-328.
5. Krauer B., Dayer P., Anner R. Changes in serum albumin and alpha 1-acid glycoprotein concentrations during pregnancy: an analysis of fetal-maternal pairs. Br J Obstet Gynaecol 1984, 91(9):875-881.
6. Davis M., Simmons C.J., Dordoni B., et al. Induction of hepatic enzymes during normal human pregnancy. J Obstet Gynaecol Br Commonw 1973, 80(8):690-694.
7. Juchau M.R., Mirkin D.L., Zachariah P.K. Interactions of various 19-nor steroids with human placental microsomal cytochrome P-450 (P-450hpm). Chem Biol Interact 1976, 15(4):337-347.
8. Zaske D.E., Cipolle R.J., Strate R.G., et al. Rapid gentamicin elimination in obstetric patients. Obstet Gynecol 1980, 56(5):559-564.
9. Watts D.H., Brown Z.A., Tartaglione T., et al. Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis 1991, 163(2):226-232.
10. Best B.M., Mirochnick M., Capparelli E.V., et al. Impact of pregnancy on abacavir pharmacokinetics. AIDS 2006, 20(4):553-560.
11. Burchett SK, Best B, Mirochnick M, et al, for the PACTG P1026s Team. Tenofovir pharmacokinetics during pregnancy, at delivery and postpartum [abstract 738b]. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles (CA), February 25-28, 2007.
12. Wang Y., Livingston E., Patil S., et al. Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus-infected pregnant women and their neonates: an AIDS clinical trials group study. J Infect Dis 1999, 180(5):1536-1541.
13. Best BM, Stek A, Hu C, et al, for the PACTG/IMPAACT P1026s Team. High-dose lopinavir and standard-dose emtricitabine pharmacokinetics during pregnancy and postpartum [abstract #629]. The 15th Conference on Retroviruses and Opportunistic Infections Boston, February, 2008. Available at: Accessed November 14, 2008. http://www.retroconference.org/2008/PDFs/629.pdf.
14. Sale M., Sheiner L.B., Volberding P., et al. Zidovudine response relationships in early human immunodeficiency virus infection. Clin Pharmacol Ther 1993, 54(5):556-566.
15. Moodley J., Moodley D., Pillay K., et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998, 178(5):1327-1333.
16. Wade N.A., Unadkat J.D., Huang S., et al. Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: pediatric AIDS Clinical Trials Group protocol 332. J Infect Dis 2004, 190(12):2167-2174.
17. Hirt D, Urien S, Rey E, et al. Population pharmacokinetics of emtricitabine in HIV-infected pregnant women and their neonates: TEmAA ANRS 12109 [abstract 626]. 15th Conference on Retroviruses and Opportunistic Infections. Boston (MA), February 3-6, 2008.
18. O'Sullivan M.J., Boyer P.J., Scott G.B., et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group. Am J Obstet Gynecol 1993, 168(5):1510-1516.
19. Rodman J, Shapiro D, Jean-Philippe P, et al. Pharmacokinetics (PK) and safety of tenofovir disoproxil fumarate (TDF) in HIV-1-infected pregnant women and their infants. In: 13th Conference on Retroviruses and Opportunistic Infections. Denver (CO), February 6, 2007.
20. Taylor G.P., Lyall E.G., Back D., et al. Pharmacological implications of lengthened in-utero exposure to nevirapine. Lancet 2000, 355(9221):2134-2135.
21. Capparelli E.V., Aweeka F., Hitti J., et al. Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. HIV Med 2008, 9(4):214-220.
22. Mirochnick M., Clarke D.F., Dorenbaum A. Nevirapine: pharmacokinetic considerations in children and pregnant women. Clin Pharmacokinet 2000, 39(4):281-293.
23. Musoke P., Guay L.A., Bagenda D., et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999, 13(4):479-486.
24. Mirochnick M., Siminski S., Fenton T., et al. Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. Pediatr Infect Dis J 2001, 20(8):803-805.
25. Acosta E.P., Zorrilla C., Van Dyke R., et al. Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV Clin Trials 2001, 2(6):460-465.
26. Capparelli EV, Stek A, Best B, et al. Boosted fosamprenavir pharmacokinetics in pregnancy. In: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco (CA), February 19, 2010.
27. Kosel B.W., Beckerman K.P., Hayashi S., et al. Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS 2003, 17(8):1195-1199.
28. Mirochnick M, Stek A, Capparelli E, et al, and PACTG 1026s Protocol Team, Atazanavir pharmacokinetics with and without tenofovir during pregnancy. The 16th Conference on Retroviruses and Opportunistic Infections, Montreal (Canada), February 2, 2009.
29. Read J.S., Best B.M., Stek A.M., et al. Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum. HIV Med 2008, 9(10):875-882.
30. Stek A.M., Mirochnick M., Capparelli E., et al. Reduced lopinavir exposure during pregnancy. AIDS 2006, 20(15):1931-1939.
31. Acosta E.P., Bardeguez A., Zorrilla C.D., et al. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004, 48(2):430-436.
32. Ripamonti D., Cattaneo D., Maggiolo F., et al. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS 2007, 21(18):2409-2415.
33. Scott GB, Rodman JH, Scott WA, et al, Pharmacokinetic and virologic response to ritonavir (RTV) in combination with zidovudine (ZDV) and lamivudine (3TC) in HIV-1-infected pregnant women and their infants [abstract 794-W]. 9th Conference on Retroviruses and Opportunistic Infections. Seattle (WA), February 24-28, 2002. Available at: Accessed November 26, 2008. http://www.retroconference.org/2002/Abstract/13702.htm.
34. Haberl A, Linde R, Reitter A, et al. Use of enfuvirtide in HIV+ pregnant women. 15th Conference on Retroviruses and Opportunistic Infections [abstract 627b]. Boston (MA), February 3-6, 2008.
35. Bedri A., Gudetta B., Isehak A., et al. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet 2008, 372(9635):300-313.
36. Giuliano M., Guidotti G., Andreotti M., et al. Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load: a study within the Drug Resource Enhancement Against AIDS and Malnutrition Program. J Acquir Immune Defic Syndr 2007, 44(3):286-291.
37. Kumwenda N.I., Hoover D.R., Mofenson L.M., et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 2008, 359(2):119-129.
38. Shetty A.K., Coovadia H.M., Mirochnick M.M., et al. Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. J Acquir Immune Defic Syndr 2003, 34(5):482-490.
39. Shapiro R.L., Holland D.T., Capparelli E., et al. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis 2005, 192(5):720-727.
40. Mirochnick M., Thomas T., Capparelli E., et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2009, 53(3):1170-1176.
41. Schneider S., Peltier A., Gras A., et al. Efavirenz in human breast milk, mothers', and newborns' plasma. J Acquir Immune Defic Syndr 2008, 48(4):450-454.
42. Marciano T., Wershil B.K. The ontogeny and developmental physiology of gastric acid secretion. Curr Gastroenterol Rep 2007, 9(6):479-481.
43. Grand R.J., Sutphen J.L., Montgomery R.K. The immature intestine: implications for nutrition of the neonate. Ciba Found Symp 1979, 70:293-311.
44. Anderson G.D., Lynn A.M. Optimizing pediatric dosing: a developmental pharmacologic approach. Pharmacotherapy 2009, 29(6):680-690.
45. Blum MR, Ndiweni D, Chittick G, et al. Steady-state pharmacokinetic evaluation of emtricitabine in neonates exposed to HIV in utero [abstract 568]. 13th Conference on Retroviruses and Opportunistic Infections. Denver (CO), February 5-9, 2006.
46. Moodley D., Pillay K., Naidoo K., et al. Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours. J Clin Pharmacol 2001, 41(7):732-741.
47. Rongkavilit C., Thaithumyanon P., Chuenyam T., et al. Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates. Antimicrob Agents Chemother 2001, 45(12):3585-3590.
48. Capparelli E.V., Mirochnick M., Dankner W.M., et al. Pharmacokinetics and tolerance of zidovudine in preterm infants. J Pediatr 2003, 142(1):47-52.
49. Mirochnick M., Fenton T., Gagnier P., et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998, 178(2):368-374.
50. Guay L.A., Musoke P., Fleming T., et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999, 354(9181):795-802.
51. Mirochnick M., Dorenbaum A., Blanchard S., et al. Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. J Acquir Immune Defic Syndr 2003, 33(2):153-156.
52. Mirochnick M, Nielsen-Saines K, Pilotto JH, et al, and NICHD/HPTN 040/PACTG 1043 Protocol Team. Nelfinavir pharmacokinetics with an increased dose during the first two weeks of life. The 15th Conference on Retroviruses and Opportunistic Infections, Boston (MA), February 4, 2008.
53. Townsend C.L., Cortina-Borja M., Peckham C.S., et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008, 22(8):973-981.
54. Boer K., Nellen J.F., Patel D., et al. The AmRo study: pregnancy outcome in HIV-1-infected women under effective highly active antiretroviral therapy and a policy of vaginal delivery. BJOG 2007, 114(2):148-155.
55. Centers for Disease Control Prevention (CDC), Mofenson L.M., Taylor A.W., et al. Achievements in public health. Reduction in perinatal transmission of HIV infection-United States, 1985-2005. MMWR Morb Mortal Wkly Rep 2006, 55(21):592-597.
56. McKenna M.T., Hu X. Recent trends in the incidence and morbidity that are associated with perinatal human immunodeficiency virus infection in the United States. Am J Obstet Gynecol 2007, 197(Suppl 3):S10-S16.
57. Dube M.P., Sattler F.R. Metabolic complications of antiretroviral therapies. AIDS Clin Care 1998, 10(6):41-44.
58. Watts D.H., Balasubramanian R., Maupin R.T., et al. Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. Am J Obstet Gynecol 2004, 190(2):506-516.
59. Hitti J., Andersen J., McComsey G., et al. Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. Am J Obstet Gynecol 2007, 196(4). 331 e1-331 e7.
60. Powderly W.G. Long-term exposure to lifelong therapies. J Acquir Immune Defic Syndr 2002, 29(Suppl 1):S28-S40.
61. Ibdah J.A., Bennett M.J., Rinaldo P., et al. A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. N Engl J Med 1999, 340(22):1723-1731.
62. Food and Drug Administration Important drug warning: retyped text of a letter from Bristol-Myers Squibb Available at:, Accessed October 15, 2002. http://www.fda.gov/medwatch/safety/2001/zerit%26videx_letter.htm.
63. Sarner L., Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Infect 2002, 78(1):58-59.
64. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States Available at:, Accessed May 24, 2010. http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf.
65. Patel S.M., Johnson S., Belknap S.M., et al. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Acquir Immune Defic Syndr 2004, 35(2):120-125.
66. Mazhude C., Jones S., Murad S., et al. Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash. AIDS 2002, 16(11):1566-1568.
67. Bersoff-Matcha S.J., Miller W.C., Aberg J.A., et al. Sex differences in nevirapine rash. Clin Infect Dis 2001, 32(1):124-129.
68. Knudtson E., Para M., Boswell H., et al. Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus. Obstet Gynecol 2003, 101(5 Pt 2):1094-1097.
69. Hitti J., Frenkel L.M., Stek A.M., et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr 2004, 36(3):772-776.
70. Lyons F., Hopkins S., Kelleher B., et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med 2006, 7(4):255-260.
71. Baylor M.S., Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004, 35(5):538-539.
72. Ouyang D.W., Shapiro D.E., Lu M., et al. Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure. AIDS 2009, 23(18):2425-2430.
73. Ouyang D.W., Brogly S.B., Lu M., et al. Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals. AIDS 2010, 24(1):109-114.
74. Public Health Service Task Force Recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States Available at:, Accessed November 11, 2008. http://aidsinfo.nih.gov/contentfiles/PerinatalGL.
75. Grosch-Woerner I., Puch K., Maier R.F., et al. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women. HIV Med 2008, 9(1):6-13.
76. Thorne C., Patel D., Newell M.L. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004, 18(17):2337-2339.
77. Townsend C.L., Cortina-Borja M., Peckham C.S., et al. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 2007, 21(8):1019-1026.
78. Tuomala R.E., Shapiro D.E., Mofenson L.M., et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002, 346(24):1863-1870.
79. Tuomala R.E., Watts D.H., Li D., et al. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr 2005, 38(4):449-473.
80. Kourtis A.P., Schmid C.H., Jamieson D.J., et al. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 2007, 21(5):607-615.
81. Watts H. Management of human immunodeficiency virus infection in pregnancy. N Engl J Med 2002, 346:1879-1891.
82. Mills J.L. Protecting the embryo from X-rated drugs. N Engl J Med 1995, 333(2):124-125.
83. Lammer E.J., Chen D.T., Hoar R.M., et al. Retinoic acid embryopathy. N Engl J Med 1985, 313(14):837-841.
84. Culnane M., Fowler M., Lee S.S., et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA 1999, 281(2):151-157.
85. Chotpitayasunondh T., Vanprapar N., Simonds R.J., et al. Safety of late in utero exposure to zidovudine in infants born to human immunodeficiency virus-infected mothers: Bangkok. Bangkok Collaborative Perinatal HIV Transmission Study Group. Pediatrics 2001, 107(1):E5.
86. Chaisilwattana P., Chokephaibulkit K., Chalermchockcharoenkit A., et al. Short-course therapy with zidovudine plus lamivudine for prevention of mother-to-child transmission of human immunodeficiency virus type 1 in Thailand. Clin Infect Dis 2002, 35(11):1405-1413.
87. Antiretroviral Pregnancy Registry Steering Committee Antiretroviral Pregnancy Registry international interim report for 1 Jan 1989-31 July 2009 2009, Registry Coordinating Center, Wilmington (NC), Available at:, Accessed May 5, 2010. http://www.APRegistry.com.
88. Townsend C.L., Tookey P.A., Cortina-Borja M., et al. Antiretroviral therapy and congenital abnormalities in infants born to HIV-1-infected women in the United Kingdom and Ireland, 1990 to 2003. J Acquir Immune Defic Syndr 2006, 42(1):91-94.
89. Fleming T.R. Evaluating the safety of interventions for prevention of perinatal transmission of HIV. Ann N Y Acad Sci 2000, 918:201-211.
90. Sustiva [package insert]. Wilmington, DE: Dupont Pharmaceuticals Company; 2000.
91. Fundaro C., Genovese O., Rendeli C., et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 2002, 16(2):299-300.
92. De Santis M., Carducci B., De Santis L., et al. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med 2002, 162(3):355.
93. Saitoh A., Hull A.D., Franklin P., et al. Myelomeningocele in an infant with intrauterine exposure to efavirenz. J Perinatol 2005, 25(8):555-556.
94. Rescriptor [package insert]. La Jolla, CA: Agouron Pharmaceuticals; 2001.
95. Antoniou T., Park-Wyllie L.Y., Tseng A.L. Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection. Pharmacotherapy 2003, 23(1):29-43.
96. Tarantal A.F., Marthas M.L., Shaw J.P., et al. Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20(4):323-333.
97. Tarantal A.F., Castillo A., Ekert J.E., et al. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr 2002, 29(3):207-220.
98. Lanzafame M., Lattuada E., Rapagna F., et al. Tenofovir-associated kidney diseases and interactions between tenofovir and other antiretrovirals. Clin Infect Dis 2006, 42(11):1656-1657. author reply 1658.
99. Antoniou T., Raboud J., Chirhin S., et al. Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med 2005, 6(4):284-290.
100. Izzedine H., Hulot J.S., Villard E., et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 2006, 194(11):1481-1491.
101. Gafni R.I., Hazra R., Reynolds J.C., et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 2006, 118(3):e711-e718.
102. Purdy J.B., Gafni R.I., Reynolds J.C., et al. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr 2008, 152(4):582-584.
103. Giacomet V., Mora S., Martelli L., et al. A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. J Acquir Immune Defic Syndr 2005, 40(4):448-450.
104. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents December 1, 2009; 1-161, Department of Health and Human Services, Available at, Accessed May 5, 2010. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
105. Martin J.L., Brown C.E., Matthews-Davis N., et al. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994, 38(12):2743-2749.
106. Brinkman K., ter Hofstede H.J., Burger D.M., et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998, 12(14):1735-1744.
107. Blanche S., Tardieu M., Rustin P., et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999, 354(9184):1084-1089.
108. Cooper ER, DiMauro S, Sullivan M, et al. Biopsy-confirmed mitochondrial dysfunction in an HIV-exposed infant whose mother received combination antiretrovirals during the last 4 weeks of pregnancy [abstract TUPEB4394 2004]. Presented at the 15th International AIDS Conference. Bangkok (Thailand), July 11-16, 2004.
109. Bulterys M., Nesheim S., Abrams E.J., et al. Lack of evidence of mitochondrial dysfunction in the offspring of HIV-infected women. Retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal AIDS Collaborative Transmission Study. Ann N Y Acad Sci 2000, 918:212-221.
110. Lindegren M.L., Rhodes P., Gordon L., et al. Drug safety during pregnancy and in infants. Lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance. Ann N Y Acad Sci 2000, 918:222-235.
111. Dominguez K., Bertolli J., Fowler M., et al. Lack of definitive severe mitochondrial signs and symptoms among deceased HIV-uninfected and HIV-indeterminate children < or = 5 years of age, Pediatric Spectrum of HIV Disease project (PSD), USA. Ann N Y Acad Sci 2000, 918:236-246.
112. Lange J, Stellato R, Brinkman K, et al. Review of neurological adverse events in relation to mitochondrial dysfunction in the prevention of mother to child transmission of HIV: PETRA Study. Presented at the Second Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants [abstract]. Montreal (Canada), September 1-6, 1999.
113. European Collaborative Study Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003, 32(4):380-387.
114. Blanche S., Tardieu M., Benhammou V., et al. Mitochondrial dysfunction following perinatal exposure to nucleoside analogues. AIDS 2006, 20(13):1685-1690.
115. Mugabo P., Cotton M., Smith J., et al. Nevirapine pharmacokinetics in premature infants. Can J Clin Pharmacol 2008, 15:e420-e781.
116. McArthur M.A., Kalu S.U., Foulks A.R., et al. Twin preterm neonates with cardiac toxicity related to lopinavir/ritonavir therapy. Pediatr Infect Dis J 2009, 28(12):1127-1129.
117. Lopriore E., Rozendaal L., Gelinck L.B., et al. Twins with cardiomyopathy and complete heart block born to an HIV-infected mother treated with HAART. AIDS 2007, 21(18):2564-2565.
118. Haubrich R.H., Little S.J., Currier J.S., et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS 1999, 13(9):1099-1107.
119. Maggiolo F., Ravasio L., Ripamonti D., et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 2005, 40(1):158-163.
120. Bangsberg D.R. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006, 43(7):939-941.
121. Bardeguez A.D., Lindsey J.C., Shannon M., et al. Adherence to antiretrovirals among US women during and after pregnancy. J Acquir Immune Defic Syndr 2008, 48(4):408-417.
122. King T.L., Murphy P.A. Evidence-based approaches to managing nausea and vomiting in early pregnancy. J Midwifery Womens Health 2009, 54(6):430-444.
123. Badell M.L., Ramin S.M., Smith J.A. Treatment options for nausea and vomiting during pregnancy. Pharmacotherapy 2006, 26(9):1273-1287.
124. Kunstel K. AIDS/HIV in pregnancy. Handbook of nutrition and pregnancy 2008, 161-176. Humana Press, Totowa (NJ). C.J. Lammi-Keefe, S.C. Couch, E.H. Philipson (Eds.).
125. Ostrop N.J., Hallett K.A., Gill M.J. Long-term patient adherence to antiretroviral therapy. Ann Pharmacother 2000, 34(6):703-709.
126. Hazra R., Siberry G.K., Mofenson L.M. Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. Annu Rev Med 2010, 61:169-185.
127. de Ruiter A., Mercey D., Anderson J., et al. British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med 2008, 9(7):452-502.
128. Ferguson W, Good M, Walksh A, et al. Four weeks of neonatal antiretroviral therapy (ART) is sufficient to optimally prevent mother to child transmission (PMTCT) of HIV [abstract H-459]. 48th Annual ICAAC/IDSA 46th Annual Meeting. Washington, DC, October 25-28, 2008. p. 400.
129. Mandelbrot L., Landreau-Mascaro A., Rekacewicz C., et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001, 285(16):2083-2093.
130. Lambert J.S., Nogueira S.A., Abreu T., et al. A pilot study to evaluate the safety and feasibility of the administration of AZT/3TC fixed dose combination to HIV infected pregnant women and their infants in Rio de Janeiro, Brazil. Sex Transm Infect 2003, 79(6):448-452.
131. Mirochnick M., Stek A., Acevedo M., et al. Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life. J Acquir Immune Defic Syndr 2005, 39(2):189-194.